Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02611167 · ClinicalTrials.gov registry record · Phase 1
Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease
A Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02611167: Completed Phase 1 study, sponsored by The University of Texas Health Science Center, Houston.
NCT02611167 is a Phase 1 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 20 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02611167, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, feasibility, and efficacy of intravenous allogeneic bone marrow-derived mesenchymal stem cell (MSC) therapy for idiopathic Parkinson's disease (iPD).
Primary Outcome
Adverse events include renal failure, liver failure, and hemolytic anemia.
Interventions
- BIOLOGICAL Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)
- BIOLOGICAL Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)
- BIOLOGICAL Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)
- BIOLOGICAL Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2019-09-18 |
| Phase | Phase 1 |
What the finished NCT02611167 record still lists
NCT02611167 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (67% lower).
The record links to 0 conditions, and to 4 interventions - of which Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) is the first listed.
NCT02611167 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02611167 about?
NCT02611167 is a clinical study titled "Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy for Idiopathic Parkinson's Disease". The purpose of this study is to assess the safety, feasibility, and efficacy of intravenous allogeneic bone marrow-derived mesenchymal stem cell (MSC) therapy for idiopathic Parkinson's disease (iPD).
What is the current status of trial NCT02611167?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2017-11-01. Estimated completion is 2019-09-18.
What interventions are being tested in trial NCT02611167?
The interventions under investigation include: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg) (BIOLOGICAL), Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg) (BIOLOGICAL), Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg) (BIOLOGICAL), Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02611167?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02611167's enrollment target sits among peer trials
20 1629th of 2000 higher than 285 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI